Insider Selling: Pediatrix Medical Group (NYSE:MD) CEO Sells 23,000 Shares of Stock

by · The Markets Daily

Pediatrix Medical Group, Inc. (NYSE:MD – Get Free Report) CEO Mark Ordan sold 23,000 shares of the firm’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $22.41, for a total transaction of $515,430.00. Following the sale, the chief executive officer owned 302,805 shares in the company, valued at approximately $6,785,860.05. This represents a 7.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Pediatrix Medical Group Price Performance

Shares of Pediatrix Medical Group stock traded up $0.23 during trading hours on Wednesday, reaching $22.55. The stock had a trading volume of 806,300 shares, compared to its average volume of 807,074. The stock’s 50 day moving average is $20.62 and its 200 day moving average is $16.88. The company has a current ratio of 1.83, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. Pediatrix Medical Group, Inc. has a twelve month low of $11.84 and a twelve month high of $24.99. The firm has a market capitalization of $1.94 billion, a PE ratio of 11.87 and a beta of 0.77.

Pediatrix Medical Group (NYSE:MD – Get Free Report) last announced its quarterly earnings results on Monday, November 3rd. The company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.21. The firm had revenue of $492.88 million during the quarter, compared to analyst estimates of $476.45 million. Pediatrix Medical Group had a return on equity of 20.45% and a net margin of 8.44%.Pediatrix Medical Group’s revenue for the quarter was down 3.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.44 EPS. Equities analysts expect that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pediatrix Medical Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in MD. LPL Financial LLC raised its position in shares of Pediatrix Medical Group by 55.5% in the first quarter. LPL Financial LLC now owns 144,318 shares of the company’s stock valued at $2,091,000 after buying an additional 51,490 shares during the last quarter. Invesco Ltd. boosted its position in Pediatrix Medical Group by 9.3% during the first quarter. Invesco Ltd. now owns 863,269 shares of the company’s stock worth $12,509,000 after acquiring an additional 73,157 shares during the last quarter. Nuveen LLC purchased a new stake in Pediatrix Medical Group during the 1st quarter valued at about $8,024,000. Russell Investments Group Ltd. raised its holdings in Pediatrix Medical Group by 2.9% in the 1st quarter. Russell Investments Group Ltd. now owns 219,184 shares of the company’s stock valued at $3,176,000 after acquiring an additional 6,127 shares during the last quarter. Finally, Fox Run Management L.L.C. acquired a new stake in Pediatrix Medical Group in the 1st quarter valued at about $345,000. Institutional investors and hedge funds own 97.71% of the company’s stock.

Analyst Ratings Changes

MD has been the subject of several research analyst reports. Truist Financial upped their target price on Pediatrix Medical Group from $17.00 to $24.00 and gave the stock a “hold” rating in a research note on Monday, November 10th. Zacks Research raised shares of Pediatrix Medical Group from a “hold” rating to a “strong-buy” rating in a report on Friday, November 21st. Wall Street Zen raised shares of Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 4th. Leerink Partners lifted their target price on shares of Pediatrix Medical Group from $14.50 to $17.00 and gave the company a “market perform” rating in a research report on Friday, September 5th. Finally, UBS Group upped their price target on shares of Pediatrix Medical Group from $16.50 to $23.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $21.00.

Get Our Latest Research Report on Pediatrix Medical Group

Pediatrix Medical Group Company Profile

(Get Free Report)

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.

Further Reading